234 related articles for article (PubMed ID: 37279388)
1. MUC1 Glycopeptide Vaccine Modified with a GalNAc Glycocluster Targets the Macrophage Galactose C-type Lectin on Dendritic Cells to Elicit an Improved Humoral Response.
Gabba A; Attariya R; Behren S; Pett C; van der Horst JC; Yurugi H; Yu J; Urschbach M; Sabin J; Birrane G; Schmitt E; van Vliet SJ; Besenius P; Westerlind U; Murphy PV
J Am Chem Soc; 2023 Jun; 145(24):13027-13037. PubMed ID: 37279388
[TBL] [Abstract][Full Text] [Related]
2. Tumor-associated Tn-MUC1 glycoform is internalized through the macrophage galactose-type C-type lectin and delivered to the HLA class I and II compartments in dendritic cells.
Napoletano C; Rughetti A; Agervig Tarp MP; Coleman J; Bennett EP; Picco G; Sale P; Denda-Nagai K; Irimura T; Mandel U; Clausen H; Frati L; Taylor-Papadimitriou J; Burchell J; Nuti M
Cancer Res; 2007 Sep; 67(17):8358-67. PubMed ID: 17804752
[TBL] [Abstract][Full Text] [Related]
3. The C-type lectin MGL expressed by dendritic cells detects glycan changes on MUC1 in colon carcinoma.
Saeland E; van Vliet SJ; Bäckström M; van den Berg VC; Geijtenbeek TB; Meijer GA; van Kooyk Y
Cancer Immunol Immunother; 2007 Aug; 56(8):1225-36. PubMed ID: 17195076
[TBL] [Abstract][Full Text] [Related]
4. Delineating binding modes of Gal/GalNAc and structural elements of the molecular recognition of tumor-associated mucin glycopeptides by the human macrophage galactose-type lectin.
Marcelo F; Garcia-Martin F; Matsushita T; Sardinha J; Coelho H; Oude-Vrielink A; Koller C; André S; Cabrita EJ; Gabius HJ; Nishimura S; Jiménez-Barbero J; Cañada FJ
Chemistry; 2014 Dec; 20(49):16147-55. PubMed ID: 25324212
[TBL] [Abstract][Full Text] [Related]
5. Calorimetric Analysis of the Interplay between Synthetic Tn Antigen-Presenting MUC1 Glycopeptides and Human Macrophage Galactose-Type Lectin.
Beckwith DM; FitzGerald FG; Rodriguez Benavente MC; Mercer ER; Ludwig AK; Michalak M; Kaltner H; Kopitz J; Gabius HJ; Cudic M
Biochemistry; 2021 Feb; 60(7):547-558. PubMed ID: 33560106
[TBL] [Abstract][Full Text] [Related]
6. Glycopeptides as Targets for Dendritic Cells: Exploring MUC1 Glycopeptides Binding Profile toward Macrophage Galactose-Type Lectin (MGL) Orthologs.
Artigas G; Monteiro JT; Hinou H; Nishimura SI; Lepenies B; Garcia-Martin F
J Med Chem; 2017 Nov; 60(21):9012-9021. PubMed ID: 29045792
[TBL] [Abstract][Full Text] [Related]
7. Glycosidic Tn-based vaccines targeting dermal dendritic cells favor germinal center B-cell development and potent antibody response in the absence of adjuvant.
Freire T; Zhang X; Dériaud E; Ganneau C; Vichier-Guerre S; Azria E; Launay O; Lo-Man R; Bay S; Leclerc C
Blood; 2010 Nov; 116(18):3526-36. PubMed ID: 20720186
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and immunological evaluation of a MUC1 glycopeptide incorporated into l-rhamnose displaying liposomes.
Sarkar S; Salyer AC; Wall KA; Sucheck SJ
Bioconjug Chem; 2013 Mar; 24(3):363-75. PubMed ID: 23444835
[TBL] [Abstract][Full Text] [Related]
9. Targeting of macrophage galactose-type C-type lectin (MGL) induces DC signaling and activation.
Napoletano C; Zizzari IG; Rughetti A; Rahimi H; Irimura T; Clausen H; Wandall HH; Belleudi F; Bellati F; Pierelli L; Frati L; Nuti M
Eur J Immunol; 2012 Apr; 42(4):936-45. PubMed ID: 22531918
[TBL] [Abstract][Full Text] [Related]
10. Identification of a secondary binding site in human macrophage galactose-type lectin by microarray studies: Implications for the molecular recognition of its ligands.
Marcelo F; Supekar N; Corzana F; van der Horst JC; Vuist IM; Live D; Boons GPH; Smith DF; van Vliet SJ
J Biol Chem; 2019 Jan; 294(4):1300-1311. PubMed ID: 30504228
[TBL] [Abstract][Full Text] [Related]
11. Tumor-associated MUC1 glycopeptide epitopes are not subject to self-tolerance and improve responses to MUC1 peptide epitopes in MUC1 transgenic mice.
Ryan SO; Vlad AM; Islam K; Gariépy J; Finn OJ
Biol Chem; 2009 Jul; 390(7):611-8. PubMed ID: 19426130
[TBL] [Abstract][Full Text] [Related]
12. Tn antigen interactions of macrophage galactose-type lectin (MGL) in immune function and disease.
Tumoglu B; Keelaghan A; Avci FY
Glycobiology; 2023 Dec; 33(11):879-887. PubMed ID: 37847609
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of MUC1-derived glycopeptide bearing a novel triazole STn analog.
Marchiori MF; Bortot LO; Carvalho I; Campo VL
Carbohydr Res; 2020 Dec; 498():108155. PubMed ID: 33010570
[TBL] [Abstract][Full Text] [Related]
14. The Breast Cancer-Associated Glycoforms of MUC1, MUC1-Tn and sialyl-Tn, Are Expressed in COSMC Wild-Type Cells and Bind the C-Type Lectin MGL.
Beatson R; Maurstad G; Picco G; Arulappu A; Coleman J; Wandell HH; Clausen H; Mandel U; Taylor-Papadimitriou J; Sletmoen M; Burchell JM
PLoS One; 2015; 10(5):e0125994. PubMed ID: 25951175
[TBL] [Abstract][Full Text] [Related]
15. Tumor-associated O-glycans of MUC1: Carriers of the glyco-code and targets for cancer vaccine design.
Beckwith DM; Cudic M
Semin Immunol; 2020 Feb; 47():101389. PubMed ID: 31926647
[TBL] [Abstract][Full Text] [Related]
16. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance.
Sørensen AL; Reis CA; Tarp MA; Mandel U; Ramachandran K; Sankaranarayanan V; Schwientek T; Graham R; Taylor-Papadimitriou J; Hollingsworth MA; Burchell J; Clausen H
Glycobiology; 2006 Feb; 16(2):96-107. PubMed ID: 16207894
[TBL] [Abstract][Full Text] [Related]
17. Microarray Analysis of Antibodies Induced with Synthetic Antitumor Vaccines: Specificity against Diverse Mucin Core Structures.
Pett C; Cai H; Liu J; Palitzsch B; Schorlemer M; Hartmann S; Stergiou N; Lu M; Kunz H; Schmitt E; Westerlind U
Chemistry; 2017 Mar; 23(16):3875-3884. PubMed ID: 27957769
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and immunological evaluation of the unnatural β-linked mucin-1 Thomsen-Friedenreich conjugate.
Wu X; McFall-Boegeman H; Rashidijahanabad Z; Liu K; Pett C; Yu J; Schorlemer M; Ramadan S; Behren S; Westerlind U; Huang X
Org Biomol Chem; 2021 Mar; 19(11):2448-2455. PubMed ID: 33645601
[TBL] [Abstract][Full Text] [Related]
19. Immunization with a Synthetic Human MUC1 Glycopeptide Vaccine against Tumor-Associated MUC1 Breaks Tolerance in Human MUC1 Transgenic Mice.
Stergiou N; Glaffig M; Jonuleit H; Schmitt E; Kunz H
ChemMedChem; 2017 Sep; 12(17):1424-1428. PubMed ID: 28675699
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of MUC1 glycopeptide thioesters and ligation via direct aminolysis.
Wilkinson BL; Chun CK; Payne RJ
Biopolymers; 2011; 96(2):137-46. PubMed ID: 20564042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
